Safety Profile Optimization of Glucose-Regulated Insulin Formulations

Information

  • Research Project
  • 7108129
  • ApplicationId
    7108129
  • Core Project Number
    R44DK069870
  • Full Project Number
    2R44DK069870-03
  • Serial Number
    69870
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/2004 - 20 years ago
  • Project End Date
    6/30/2007 - 17 years ago
  • Program Officer Name
    RABADAN-DIEHL, CRISTINA
  • Budget Start Date
    7/1/2006 - 18 years ago
  • Budget End Date
    6/30/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    3
  • Suffix
  • Award Notice Date
    6/26/2006 - 18 years ago
Organizations

Safety Profile Optimization of Glucose-Regulated Insulin Formulations

[unreadable] DESCRIPTION (provided by applicant): SmartCells has developed Smartlnsulin, a once-a-day, injectable formulation of insulin for the treatment of diabetes. Unlike pump- and cell-based systems, Smartlnsulin is a "smart" hydrogel that self-assembles from two biomolecular building blocks: a glycosylated insulin-polymer conjugate (IPC) and a multimeric glucose-binding molecule (GBM). In SBIR Phase I of this grant, proof-of-concept efficacy and safety was demonstrated both in vitro and in vivo using a diabetic Sprague-Dawley rat model. SmartCells seeks Phase II funds to rigorously optimize the in vivo safety profiles of Smartlnsulin in non-diabetic Sprague Dawley (SD) rat models as a precursor to beginning IND-enabling preclinical studies on Smartlnsulin. With Phase II funds, SmartCells seeks to: 1. Identify PEG-Con A GBM candidates with minimal serum half-life that are chemically stable, such that no immunoreactive, non-PEGylated Con A is exposed in vivo. 2. Identify formulations with minimal local and systemic single-dose toxicity as measured by custom ELISAs, histology, and spleenocyte phenotyping. 3. Develop a hyperglycemic clamp to investigate Smartlnsulin pharmacokinetics in non-diabetic rats. 4. Confirm minimal local and systemic toxicity of daily injections following Smartlnsulin release under hyperglycemic clamp conditions in non-diabetic rats. The impacts on public health as a result of this project are potentially significant. Poor glycemic control has been shown to cause a host of diabetic complications which result in over $54 billion annually in medical costs. The landmark Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS), have clinically proven that tighter glycemic control, as measured by lower glycosylated hemoglobin A1c (HbA1c) levels, significantly reduces the incidence of these complications. Thus, Smartlnsulin seeks to provide tighter glycemic control, lowered HbA1c levels, and decreased incidence of diabetic complications. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    749991
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:749991\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SMARTCELLS, INC.
  • Organization Department
  • Organization DUNS
    143319973
  • Organization City
    BEVERLY
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01951
  • Organization District
    UNITED STATES